This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
“ABT-493 is more potent against genotype 3 than other HCV protease inhibitors, including products being developed by Merck (grazoprevir) and Gilead (GS-9451), and ABT-530 has demonstrated higher potency than most other NS5A inhibitors across all genotypes.”
A combination of two experimental direct-acting antivirals developed by AbbVie cured 93%-97% of people with genotype 3 hepatitis C infection after a 12-week course of treatment, Paul Kwo of Indiana University School of Medicine reported on Monday at the 2015 AASLD Liver Meeting in San Francisco.
Genotype 3 infection is associated with an increased risk of fibrosis progression and liver cancer (hepatocellular carcinoma) compared to other genotypes, making affordable and effective treatment options for this group of patients an important unmet need.
Genotype 3 hepatitis C infection is more difficult to cure than other genotypes of hepatitis C, requiring a longer course of treatment with most regimens. The only currently approved 12-week interferon-free regimen for treatment of genotype 3 consists of daclatasvir (Daklinza) and sofosbuvir (Sovaldi). Almost 30% of worldwide hepatitis C infections are estimated to be genotype 3, with a particular concentration in the Indian sub-continent and among populations of Indian origin living elsewhere. Genotype 3 is also widespread in the Russian Federation, Scandinavia, Thailand, Brazil and Australia.
The SURVEYOR-2 study assessed the effectiveness and safety of two experimental next-generation direct-acting antivirals, with or without ribavirin, at different doses. ABT-493 is an HCV NS3/4A protease inhibitor active against all genotypes of hepatitis C. ABT-530 is a NS5A inhibitor also active against all genotypes of HCV. Both agents are active against common variants that confer resistance to first-generation agents of their classes. ABT-493 is more potent against genotype 3 than other HCV protease inhibitors, including products being developed by Merck (grazoprevir) and Gilead (GS-9451), and ABT-530 has demonstrated higher potency than most other NS5A inhibitors across all genotypes.
Read more…http://www.aidsmap.com/New-AbbVie-hepatitis-C-combination-cures-93-97-with-genotype-3/page/3015412/